咖啡摄入与晚期或转移性结直肠癌患者生存的关联
该研究基于CALGB/SWOG 80405试验中1171例初治晚期或转移性结直肠癌患者的前瞻性观察队列,用半定量食物频率问卷评估咖啡摄入。结果显示咖啡摄入量增加与疾病进展和死亡风险降低相关,每日2-3杯与不喝咖啡者相比OS和PFS的HR均为0.82,每日≥4杯者OS的HR为0.64,含咖啡因和脱咖啡因咖啡均见关联。
要点
- 每日2-3杯 vs 不喝咖啡者:OS的HR 0.82(95%CI 0.67-1.00),PFS的HR 0.82(95%CI 0.68-0.99)。
- 每日≥4杯者OS的HR 0.64(95%CI 0.46-0.87),PFS的HR 0.78(95%CI 0.59-1.05)。
核心结论
- 咖啡摄入可能与晚期或转移性结直肠癌患者疾病进展和死亡风险降低相关。
- 含咖啡因和脱咖啡因咖啡均观察到显著关联。
- 需进一步研究阐明潜在生物学机制。
研究设计与样本
- 前瞻性观察队列研究,纳入CALGB(Alliance)/SWOG 80405Ⅲ期试验中1171例初治局部晚期或转移性结直肠癌患者。
- 入组时用半定量食物频率问卷报告膳食摄入,暴露为每日总咖啡、脱咖啡因咖啡和含咖啡因咖啡杯数。
- 数据收集于2005年10月27日至2018年1月18日,分析于2018年5月1日至8月31日。
主要发现
- 1171例患者中694例(59%)为男性,中位年龄59岁(IQR 51-67)。
- 存活患者中位随访5.4年(第10百分位1.3年;IQR 3.2-6.3年),1092例(93%)死亡或疾病进展。
关键数值与推荐
- 每日2-3杯 vs 不喝咖啡:OS多变量HR 0.82(95%CI 0.67-1.00),PFS多变量HR 0.82(95%CI 0.68-0.99)。
- 每日≥4杯 vs 不喝咖啡:OS多变量HR 0.64(95%CI 0.46-0.87),PFS多变量HR 0.78(95%CI 0.59-1.05)。
临床怎么用
- 可为晚期或转移性结直肠癌患者提供咖啡摄入与生存关联的预后信息,但不应作为治疗推荐。
- 含咖啡因和脱咖啡因咖啡均见关联,提示非咖啡因成分可能参与。
局限性
- 为观察性队列研究,不能确立因果关系。
- 咖啡摄入基于入组时食物频率问卷自我报告,可能存在测量误差。
- 研究纳入的是临床试验人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity. Epidemiological studies have identified associations between increased coffee consumption and decreased recurrence and mortality of colorectal cancer. The association between coffee consumption and survival in patients with advanced or metastatic colorectal cancer is unknown. OBJECTIVE: To evaluate the association of coffee consumption with disease progression and death in patients with advanced or metastatic colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: This prospective observational cohort study included 1171 patients with previously untreated locally advanced or metastatic colorectal cancer who were enrolled in Cancer and Leukemia Group B (Alliance)/SWOG 80405, a completed phase 3 clinical trial comparing the addition of cetuximab and/or bevacizumab to standard chemotherapy. Patients reported dietary intake using a semiquantitative food frequency questionnaire at the time of enrollment. Data were collected from October 27, 2005, to January 18, 2018, and analyzed from May 1 to August 31, 2018. EXPOSURES: Consumption of total, decaffeinated, and caffeinated coffee measured in cups per day. MAIN OUTCOMES AND MEASURES: Overall survival (OS) and progression-free survival (PFS). RESULTS: Among the 1171 patients included in the analysis (694 men [59%]; median age, 59 [interquartile range, 51-67] years). The median follow-up time among living patients was 5.4 years (10th percentile, 1.3 years; IQR, 3.2-6.3 years). A total of 1092 patients (93%) had died or had disease progression. Increased consumption of coffee was associated with decreased risk of cancer progression (hazard ratio [HR] for 1-cup/d increment, 0.95; 95% CI, 0.91-1.00; P = .04 for trend) and death (HR for 1-cup/d increment, 0.93; 95% CI, 0.89-0.98; P = .004 for trend). Participants who consumed 2 to 3 cups of coffee per day had a multivariable HR for OS of 0.82 (95% CI, 0.67-1.00) and for PFS of 0.82 (95% CI, 0.68-0.99), compared with those who did not drink coffee. Participants who consumed at least 4 cups of coffee per day had a multivariable HR for OS of 0.64 (95% CI, 0.46-0.87) and for PFS of 0.78 (95% CI, 0.59-1.05). Significant associations were noted for both caffeinated and decaffeinated coffee. CONCLUSIONS AND RELEVANCE: Coffee consumption may be associated with reduced risk of disease progression and death in patients with advanced or metastatic colorectal cancer. Further research is warranted to elucidate underlying biological mechanisms.
引用
- Mackintosh C, Yuan C, Ou FS, et al. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020. PMID: 32940631. doi:10.1001/jamaoncol.2020.3938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。